Membrane Potential Mapping with 18F-TPP

This study is looking at a new way to image your body's cells using a special tracer called 18F-TPP. Researchers want to understand how this tracer moves through the body and how it can help them see something called "membrane potential" (ΔΨm), which is important for how cells work. They will use a PET/CT scanner and also an MRI. The main goal is to measure how much of the tracer is distributed in your body. You may be able to join if you are between 21 and 80 years old, in good general health, and willing to follow study procedures. The study plans to enroll 24 people, but its current status is unclear.

Study design: This is an interventional study planning to enroll 24 participants. It is not specified if it is randomized or blinded.
What's involved: You will have at least two visits, with the second visit up to 90 days after the first. You will undergo PET/CT scans and a separate MRI. Some scans may involve taking blood samples.
Compensation: Not stated in the trial record.
Follow-up: The primary endpoint, tracer volume of distribution, is measured at Visit 2, which is up to 90 days after the screening visit.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Membrane Potential Mapping with18F-TPP

Recruiting

PHASE1Ages 21–80InterventionalBasic science

Yale University

~24 participants

Updated 2026-08-31 on ClinicalTrials.gov

What's tested:18F-TPP

At a glance

Recruiting sites

1 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Tracers volume of distribution (VT)

Measured over Visit 2 (up to 90 days post screening visit 1)

Conditions

Membrane Potential Mapping

NCT07506616

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

Yale University PET Center
New Haven, Connecticutno site contact published
Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

Georges El Fakhri, PhD, DABR · PRINCIPAL_INVESTIGATOR · Yale University

Who to contact

Shannan Henry

[email protected]

(203) 737-5278

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Willing and able to give voluntary written informed consent

Stated willingness to comply with all study procedures and availability for the duration of the study

In good general health as evidenced by medical history, physical examination, ECG, serum/urine biochemistry and hematology tests.

If female of childbearing potential, must agree to use an acceptable method of birth control, as determined by the principal investigator, for the duration of the study.

Exclusion

Know structural heart disease (e.g. myocardial infarction)

Abnormal and clinically significant ECG (as determined by the Investigator or his/her designee) at screening.

Laboratory tests with clinically significant abnormalities at screening

Pregnancy or Lactation

MRI incompatible implants (i.e., such as pacemaker, artificial joints, non-removable body piercings) and other contraindications for MRI, such as claustrophobia, having implanted or embedded metal objects/fragments or fragments in the head or body that would present a risk during the MRI scanning procedure, or have worked with ferrous metals either as a vocation or hobby (for example, as a sheet metal worker, welder, or machinist).

Participation in other research studies involving ionizing radiation within one year of the PET scans that would cause the subject to exceed the yearly dose limits followed by the Yale University PET Center.

Subject who has current, past, or anticipated exposure to radiation in the workplace within one year of the proposed research scans that in combination with the study tracer would result in a cumulative exposure that exceeds recommended exposure limits.

Has any condition that, in the opinion of the investigator, would prevent compliance with the study protocol.

Arterial Line Exclusion: Blood donation within eight weeks of the start of the study.

Arterial Line Exclusion: History of a bleeding disorder or are currently taking anticoagulants (such as Coumadin, Heparin, Pradaxa, Xarelto).

Arterial Line Exclusion: Prothrombin Time (PT) and Partial Thromboplastin Time (PTT) greater than 5msec above the upper limit of normal.

Arterial Line Exclusion: Unable to safely discontinue or hold aspirin and other NSAID use

What this trial measures

Tracers volume of distribution (VT)Visit 2 (up to 90 days post screening visit 1)
Maps of the 18F-TPP tracer volume of distribution (VT) and ΔΨT based on quantitative analysis of PET imaging.

Trialytics